D. Heymann and . Preface, Bone Cancer, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00667499

S. S. Bielack, S. Hecker-nolting, C. Blattmann, and L. Kager, Advances in the management of osteosarcoma, 2016.

B. A. Lindsey, J. E. Markel, E. S. Kleinerman, and . Osteosarcoma-overview, , vol.4, pp.25-43

V. Nataraj, S. Rastogi, S. A. Khan, M. C. Sharma, S. Agarwala et al., Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: A single center experience of 102 patients, Clin. Transl. Oncol, vol.18, pp.937-944, 2016.

D. C. Allison, S. C. Carney, E. R. Ahlmann, A. Hendifar, S. Chawla et al., A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era, Sarcoma, vol.704872, 2012.

M. Heymann, H. K. Brown, and D. Heymann, Drugs in early clinical development for the treatment of osteosarcoma, Expert Opin. Investig. Drugs, vol.25, pp.1265-1280, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01466096

M. Kansara, M. W. Teng, M. J. Smyth, and D. M. Thomas, Translational biology of osteosarcoma, Nat. Rev. Cancer, vol.14, pp.722-735, 2014.

J. S. Kenkre and J. Bassett, The bone remodelling cycle, Ann. Clin. Biochem, 2018.

M. C. Walsh and Y. Choi, Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front. Immunol, vol.5, 2014.

J. Xiong, M. Onal, R. L. Jilka, R. S. Weinstein, S. C. Manolagas et al., Matrix-embedded cells control osteoclast formation, Nat. Med, vol.17, pp.1235-1241, 2011.

S. Rao, S. J. Cronin, V. Sigl, and J. M. Penninger, RANKL and RANK: From Mammalian Physiology to Cancer Treatment, Trends Cell Biol, vol.28, pp.213-223, 2018.

S. Theoleyre, Y. Wittrant, S. K. Tat, Y. Fortun, F. Redini et al., The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling, Cytokine Growth Factor Rev, vol.15, pp.457-475, 2004.

D. Santini, G. Perrone, I. Roato, L. Godio, F. Pantano et al., Expression pattern of receptor activator of NF?B (RANK) in a series of primary solid tumors and related bone metastases, J. Cell. Physiol, vol.226, pp.780-784, 2011.

K. Mori, B. Le-goff, C. Charrier, S. Battaglia, D. Heymann et al., DU145 human prostate cancer cells express functional receptor activator of NF?B: New insights in the prostate cancer bone metastasis process, vol.40, pp.981-990, 2007.

M. Sisay, G. Mengistu, and D. Edessa, The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: Potential targets for anticancer therapy, vol.10, pp.3801-3810, 2017.

V. Sigl, L. P. Jones, and J. M. Penninger, RANKL/RANK: From bone loss to the prevention of breast cancer, Open Biol, vol.6, 2016.

F. Lamoureux, P. Richard, Y. Wittrant, S. Battaglia, P. Pilet et al., Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption, Cancer Res, vol.67, pp.7308-7318, 2007.

E. Grimaud, L. Soubigou, S. Couillaud, P. Coipeau, A. Moreau et al., Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis, Am. J. Pathol, vol.163, pp.2021-2031, 2003.

T. A. Guise, The vicious cycle of bone metastases, J. Musculoskelet. Neuronal Interact, vol.2, pp.570-572, 2002.

A. G. Beristain, S. R. Narala, M. A. Di-grappa, and R. Khokha, Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells, J. Cell Sci, vol.125, pp.943-955, 2012.

B. Castaneda, Y. Simon, D. Ferbus, B. Robert, J. Chesneau et al., Role of RANKL (TNFSF11)-dependent osteopetrosis in the dental phenotype of Msx2 null mutant mice, PLoS ONE, vol.8, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01538404

Y. Chen, M. A. Di-grappa, S. D. Molyneux, T. D. Mckee, P. Waterhouse et al., RANKL blockade prevents and treats aggressive osteosarcomas, Sci. Transl. Med, vol.7, 2015.

N. Renema, B. Navet, M. Heymann, F. Lezot, and D. Heymann, RANK-RANKL signalling in cancer, Biosci. Rep, vol.36, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01644732

Z. Bago-horvath, K. Schmid, F. Rössler, K. Nagy-bojarszky, P. Funovics et al., Impact of RANK signalling on survival and chemotherapy response in osteosarcoma, Pathology, vol.46, pp.411-415, 2014.

K. Mori, B. Le-goff, M. Berreur, A. Riet, A. Moreau et al., Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B, J. Pathol, vol.211, pp.555-562, 2007.

Y. Wittrant, F. Lamoureux, K. Mori, A. Riet, A. Kamijo et al., RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells, Int. J. Oncol, vol.28, pp.261-269, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00667510

K. Trieb and R. Windhager, Receptor activator of nuclear factor ?B expression is a prognostic factor in human osteosarcoma, Oncol. Lett, vol.10, pp.1813-1815, 2015.

A. R. Safa, c-FLIP, a master anti-apoptotic regulator, Exp. Oncol, vol.34, pp.176-184, 2012.

Z. E. Stine, Z. E. Walton, B. J. Altman, A. L. Hsieh, C. V. Dang et al., , vol.5, pp.1024-1039, 2015.

E. Gonzalez-suarez, A. P. Jacob, J. Jones, R. Miller, M. P. Roudier-meyer et al., RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis, Nature, vol.468, pp.103-107, 2010.

F. Lamoureux, M. Baud'huin, L. Rodriguez-calleja, C. Jacques, M. Berreur et al., Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle, Nat. Commun, vol.5, 2014.

R. Hanada, T. Hanada, and J. M. Penninger, Physiology and pathophysiology of the RANKL/RANK system, Biol. Chem, vol.391, pp.1365-1370, 2010.

V. Duheron, E. Hess, M. Duval, M. Decossas, B. Castaneda et al., Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit, Proc. Natl. Acad. Sci, vol.108, pp.5342-5347, 2011.

V. Sigl and J. M. Penninger, RANKL/RANK-from bone physiology to breast cancer, Cytokine Growth Factor Rev, vol.25, pp.205-214, 2014.
DOI : 10.1016/j.cytogfr.2014.01.002

D. M. Thomas and K. M. Skubitz, Giant cell tumour of bone, Curr. Opin. Oncol, vol.21, pp.338-344, 2009.

T. Ren, S. Piperdi, P. Koirala, A. Park, W. Zhang et al., CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression, Oncotarget, vol.8, pp.87848-87859, 2017.
DOI : 10.18632/oncotarget.21254

URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=21254&path%5B%5D=67633

J. Canon, R. Bryant, M. Roudier, D. G. Branstetter, and W. C. Dougall, RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model, Breast Cancer Res. Treat, vol.135, pp.771-780, 2012.

F. Christoph, F. König, S. Lebentrau, B. Jandrig, H. Krause et al., RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease, World J. Urol, vol.36, pp.187-192, 2018.
DOI : 10.1007/s00345-017-2145-y

S. Casimiro, K. S. Mohammad, R. Pires, J. Tato-costa, I. Alho et al., RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro, PLoS ONE, vol.8, 2013.

R. Thirumala, M. Ramaswamy, and S. Chawla, Diagnosis and management of infectious complications in critically ill patients with cancer, Crit. Care Clin, vol.26, pp.59-91, 2010.

S. Avnet, A. Longhi, M. Salerno, J. M. Halleen, F. Perut et al., Increased osteoclast activity is associated with aggressiveness of osteosarcoma, Int. J. Oncol, vol.33, pp.1231-1238, 2008.

J. Luo, Z. Yang, Y. Ma, Z. Yue, H. Lin et al., LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption, Nat. Med, vol.22, pp.539-546, 2016.
DOI : 10.1038/nm.4076

J. Liu, W. Wei, C. Guo, N. Han, J. Pan et al., Stat3 Upregulates Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 4 Expression in Osteosarcoma Cells, BioMed Res. Int, 2013.
DOI : 10.1155/2013/310691

URL : http://downloads.hindawi.com/journals/bmri/2013/310691.pdf

W. Luo, P. Tan, M. Rodriguez, L. He, K. Tan et al., Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition, J. Biol. Chem, vol.292, pp.15525-15537, 2017.
DOI : 10.1074/jbc.m116.771931

URL : http://www.jbc.org/content/292/37/15525.full.pdf

M. J. Joliat, S. Umeda, B. L. Lyons, M. A. Lynes, and L. D. Shultz, Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma, Vivo Athens Greece, vol.16, pp.223-228, 2002.

T. Dull, R. Zufferey, M. Kelly, R. J. Mandel, M. Nguyen et al., A third-generation lentivirus vector with a conditional packaging system, J. Virol, vol.72, pp.8463-8471, 1998.

F. Lézot, J. Chesneau, B. Navet, B. Gobin, J. Amiaud et al., Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid, vol.73, pp.51-59, 2015.

S. Kamijo, A. Nakajima, K. Ikeda, K. Aoki, K. Ohya et al., Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody, Biochem. Biophys. Res. Commun, vol.347, pp.124-132, 2006.

C. Dumars, J. Ngyuen, A. Gaultier, R. Lanel, N. Corradini et al., Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma, Oncotarget, vol.7, pp.78343-78354, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01466103